ClinicalTrials.gg
WithdrawnNCT02972866RINEX32Updated Oct 9, 2019

Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis

A Phase 3 interventional study of Budesonide in Rhinitis, Allergic, Perennial, sponsored by Eurofarma Laboratorios S.A.. Withdrawn at 1 site in Brazil. Open to participants aged 12 Years to 90 Years. Per ClinicalTrials.gov, last updated 2019-10-09.

Sponsored by Eurofarma Laboratorios S.A. · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Regulatory strategy

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
12 Years to 90 Years
Sex
All
01

Study summary

This study is to evaluate non inferiority of Eurofarma budesonide nasal spary x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.

Read the detailed description

Budesonide is a medicine already very used and registered about 20 years. Eurofarma has the intention to collect more data about safety and efficacy and present them to local authority.

This study was draw to treat patients with persisntent rhinits moderate to severe in sites localted locally in Brasil.

02

Conditions studied

  • Rhinitis, Allergic, Perennial
03

In context

Rhinitis, Allergic, Perennial

178 studies on the registry are indexed under Rhinitis, Allergic, Perennial; 9 are open to participants now.

Browse Rhinitis, Allergic, Perennial studies →

Lead sponsor

Eurofarma Laboratorios S.A. is the lead sponsor of 64 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 12.
  2. History of alergic persistent rhinitis moderate to severe at least 2 years.
  3. Proved alergic using PRICK or RAST test.
  4. Nasal symptoms (NIS) > 3 and nasal obstruction >1.
  5. Indication of nasal corticorteroids use..
  6. Washout of nasal corticorteroids for 14 days.
  7. ICF.

Exclusion criteria

Exclusion Criteria:

  1. Other types of rhinitis;
  2. Asthma non controled
  3. Use of oral/injectable corticoids 30 days before screening.
  4. patients not eligible to complete diaries.
  5. patients with alergy to any substance of medicines.
  6. non controlled desease.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Noex 32mcg

    Noex/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day. Tretament of 28 days.

    Drug: Budesonide

  • Experimental
    Budecort Aqua 32 mcg

    Budecort Aqua/Budesonide 32mcg, 2 atomizations in each nostril by the morning and during the night, total of 256 mcg per day. Tretament of 28 days.

    Drug: Budesonide

Interventions

  • Suspention to nasal use, 2 atomization in each nostril during the morning and at night.

    Also known as: Noex 32mcg, Budecort Aqua 32mcg

06

What researchers measure

Primary outcomes

  1. Demonstrate non inferiority of Noex comparable with referral product Budecort Aqua in the treatment of rinithis moderate to severe during 4 weeks of treatment.

    The questionnaire Nasal Index Score (NIS) will be used to check intensity of symptons and patient will answer this questionnaire daily at home.

    Time frame: 28 days

07

Study locations

1 site
  • Allergisa pesquisa dermato-cosmética ltda
    Campinas, São Paulo, Brazil
08

References and documents

Individual participant data

Plan to share: Undecided — Undecided, but could be shared upon investigator's request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2016; primary completion for Nov 2019, 41 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2016
First posted
Nov 25, 2016
StartEst.
Jun 2016
Primary completionEst.
Nov 2019
CompletionEst.
Nov 2019
Last update
Oct 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02972866
Responsible party
Sponsor
First posted
Nov 25, 2016
Start date
Jun 2016 (estimated)
Primary completion
Nov 2019 (estimated)
Completion
Nov 2019 (estimated)
Last update
Oct 9, 2019

Study contacts

Mauro Acir Crippa Junior
principal investigator · Allergisa Pesquisa Dermato-Cosmética Ltda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion